Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F M Debruyne

Showing results (401-410 of 505) with videos related to

Pageof 51
Sort By:
Cancer Research|November 15, 1993
Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridizationY Tamimi, H G van der Poel, M M Denyn, et al.
The Journal of Urology|December 1, 1994
High energy shock waves induced increase in the local concentration of systemically given TNF-alphaE B Cornel, E Oosterwijk, J D van de Streek, et al.
Urology|March 4, 2000
Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk QuanticytB W van Rhijn, H G van der Poel, M E Boon, et al.
The American Journal of Pathology|February 1, 1992
Establishment and characterization of five new human renal tumor xenograftsA J Beniers, W P Peelen, H E Schaafsma, et al.
European Urology|January 1, 1995
A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological GroupG A Dijkman, F M Debruyne, P Fernandez del Moral, et al.
Cancer Research|May 1, 1991
Synergistic antitumor effects of rat gamma-interferon and human tumor necrosis factor alpha against androgen-dependent and -independent rat prostatic tumorsR J van Moorselaar, B T Hendriks, P van Stratum, et al.
Urology|April 1, 1989
Determination of prostatic volume by ultrasonography. A useful procedure in patients with prostatism?A J Hendrikx, W H Doesburg, A G Reintjes, et al.
European Urology|January 1, 1997
Sacral rhizotomies and electrical bladder stimulation in spinal cord injury. Part I: Clinical and urodynamic analysis. Dutch Study Group on Sacral Anterior Root StimulationE V Van Kerrebroeck, H E van der Aa, J L Bosch, et al.
European Urology|January 1, 1994
A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological GroupG A Dijkman, F M Debruyne, P Fernandez del Moral, et al.
Progress in Clinical and Biological Research|January 1, 1992
Karyometry of bladder washings for the follow up of patients with transitional cell carcinoma of the bladderH G van der Poel, G O Oosterhof, H E Schaafsma, et al.
Pageof 51

Showing results (401-410 of 505) with videos related to

Sort By:
Pageof 51
Cancer Research|November 15, 1993
Increased expression of high mobility group protein I(Y) in high grade prostatic cancer determined by in situ hybridizationY Tamimi, H G van der Poel, M M Denyn, et al.
The Journal of Urology|December 1, 1994
High energy shock waves induced increase in the local concentration of systemically given TNF-alphaE B Cornel, E Oosterwijk, J D van de Streek, et al.
Urology|March 4, 2000
Presence of carcinoma in situ and high 2C-deviation index are the best predictors of invasive transitional cell carcinoma of the bladder in patients with high-risk QuanticytB W van Rhijn, H G van der Poel, M E Boon, et al.
The American Journal of Pathology|February 1, 1992
Establishment and characterization of five new human renal tumor xenograftsA J Beniers, W P Peelen, H E Schaafsma, et al.
European Urology|January 1, 1995
A randomised trial comparing the safety and efficacy of the Zoladex 10.8-mg depot, administered every 12 weeks, to that of the Zoladex 3.6-mg depot, administered every 4 weeks, in patients with advanced prostate cancer. The Dutch South East Cooperative Urological GroupG A Dijkman, F M Debruyne, P Fernandez del Moral, et al.
Cancer Research|May 1, 1991
Synergistic antitumor effects of rat gamma-interferon and human tumor necrosis factor alpha against androgen-dependent and -independent rat prostatic tumorsR J van Moorselaar, B T Hendriks, P van Stratum, et al.
Urology|April 1, 1989
Determination of prostatic volume by ultrasonography. A useful procedure in patients with prostatism?A J Hendrikx, W H Doesburg, A G Reintjes, et al.
European Urology|January 1, 1997
Sacral rhizotomies and electrical bladder stimulation in spinal cord injury. Part I: Clinical and urodynamic analysis. Dutch Study Group on Sacral Anterior Root StimulationE V Van Kerrebroeck, H E van der Aa, J L Bosch, et al.
European Urology|January 1, 1994
A phase III randomized trial comparing the efficacy and safety of the 3-monthly 10.8-mg depot of Zoladex with the monthly 3.6-mg depot in patients with advanced prostate cancer. Dutch South East Cooperative Urological GroupG A Dijkman, F M Debruyne, P Fernandez del Moral, et al.
Progress in Clinical and Biological Research|January 1, 1992
Karyometry of bladder washings for the follow up of patients with transitional cell carcinoma of the bladderH G van der Poel, G O Oosterhof, H E Schaafsma, et al.
Pageof 51